Back to results
US 11,591,628 B2Granted
Biosynthetic heparin
AssigneeRensselaer Polytechnic Institute
InventorsMarc Douaisi, Navdeep Grover, Payel Datta, Elena Paskaleva, Lei Lin, Paul Brodfuehrer, Trevor J. Simmons, Akihiro Onishi, Makoto Hirakane, Li Fu, Kevin Li, Robert J. Linhardt, Jonathan Dordick, Daisuke Mori
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to synthesis of heparin, which may be bioequivalent to porcine USP Heparin Sodium. The synthesis may involve three intermediates starting from heparosan.
Claims18
A glycosaminoglycan comprising (a) 44-80% of N-sulfated, 2-sulfated (NS2S) disaccharide group;
- (b) 13-39% of NS disaccharide group and (c) 0.4-25% of at least one unmodified N-acetylated glucosamine group selected from OS disaccharide group and 2S disaccharide group, wherein the glycosaminoglycan has a weight average molecular weight appropriate to form a final heparin product of 15,000-19,000 Da, the percentage of heparin chains with a molecular weight of greater than 24,000 Da being not more than 20% of the total, and the ratio of chains between molecular weights of 8,000 to 16,000 Da to the percentage of chains with molecular weights of 16,000 to 24,000 Da being not less than 1.0.
Dependencies are inferred from the claim text.